AI-Designed Drugs by Isomorphic Labs Headed to Human Trials

Isomorphic Labs, a startup spun out of DeepMind, is advancing its AI-designed drugs to human clinical trials. The company's president, Max Jaderberg, shared the news at the WIRED Health conference in London. This development underscores the growing potential of AI in medicine. Isomorphic Labs has been working on a range of new medicines, which Jaderberg described as a 'broad and exciting pipeline.' The company's AI algorithms have been used to design these drugs, which aim to tackle various diseases. The move into human trials represents a crucial step in the approval process for these new treatments. As AI continues to transform the healthcare industry, Isomorphic Labs' progress is a notable example of its potential. The company's work has the potential to revolutionize the way new medicines are discovered and developed. The human trials will provide valuable insights into the efficacy and safety of these AI-designed drugs. The results of these trials will be closely watched by the medical community and could have significant implications for the future of medicine.